Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study
Javier Cortés(Vall d'Hebron Institute of Oncology), Joyce O’Shaughnessy(Texas Oncology), David Loesch(Caris Life Sciences (United States)), Joanne L. Blum(Texas Oncology), Linda T. Vahdat(Cornell University), Katarína Petráková(Masaryk Memorial Cancer Institute), P. Chollet(Centre Jean Perrin), Alexey Manikas(City Clinical Oncology Center), Véronique Dièras(Institut Curie), T. Delozier(Centre François Baclesse), Vladimir Vladimirov(Pyatigorsk Oncology Center), Fátima Cardoso(Institut Jules Bordet), Han Koh(Kaiser Permanente), Philippe Bougnoux(Centre Hospitalier Universitaire de Tours), Corina E. Dutcus(Eisai (United States)), Seth Seegobin(Eisai (Japan)), Denis Mir(Eisai (Japan)), Nicole Meneses(Eisai (United States)), J. Wanders(Eisai (United Kingdom)), Chris Twelves(University of Leeds)
Cited by 1,092
Abstract
Related Papers
Superior Survival With Capecitabine Plus Docetaxel Combination Therapy in Anthracycline-Pretreated Patients With Advanced Breast Cancer: Phase III Trial Results
Joyce O’Shaughnessy, David Miles, Svetislava J. Vukelja et al.|Journal of Clinical Oncology|2002|1.1k
Overview of Resistance to Systemic Therapy in Patients with Breast Cancer
Ana M. González-Angulo, Flavia Morales-Vásquez, Gabriel N. Hortobágyi|Advances in experimental medicine and biology|2007|916